



CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, February 16, 2023

In accordance with Article 226 of the recast Spanish Securities Market Act (*Ley del Mercado de Valores*), is hereby reported the following:

INSIDE INFORMATION

The Company announces the closure of the Phase III “Neptuno” trial with plitidepsin for the treatment of COVID-19 in hospitalized patients. The Company has made this decision due to the lack of enrollment of patients for the study given the evolution of the pandemic.

Please find attached press release that will be distributed to the media today.



PharmaMar closes recruitment for the Phase III Neptuno trial with plitidepsin for the treatment of COVID-19

- Given the evolution of the pandemic and its impact on the number of applicable patients, the Company has decided to close the study early.
- Preliminary data suggest a positive trend of plitidepsin versus the control arm.
- The final data will be published once they are fully analyzed.

Madrid, February 16th, 2023. – PharmaMar (MSE:PHM) has announced today that it is closing the Phase III “Neptuno” trial with plitidepsin for the treatment of COVID-19 in hospitalized patients. The Company has made this decision due to the lack of enrollment of patients for the study given the evolution of the pandemic.

Despite an insufficient sample of patients, a preliminary analysis suggests a positive trend, demonstrating the drug's potent activity.

PharmaMar will continue to analyze the trial data for a subsequent publication.

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage



programs under development for several types of solid cancers: lurbinectedin and ecubectedin. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

For more information:

Media Contact

Lara Vadillo – Communication Director lvadillo@pharmamar.com

Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations

José Luis Moreno – Capital Markets & Investor Relations Director

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at www.pharmamar.com